Research progress on the treatment after resistance to first generation EGFR - TKI in patients with non - small cell lung cancer
DENG Wu-sheng
SUN Jie
Abstract：Lung cancer is one of the most common malignant tumors in the world and a serious threat to human health. EGFR - TKI has become the hot topic in non - small cell lung cancer. EGFR - TKI is the first - line treatmen on EGFR gene mutations in lung cancer,EGFR - TKI has been used for first - line therapy,second - line treatment and main-tenance therapy in non - small cell lung cancer. Although the results of EGFR - TKI for patients with non - small cell lung cancer has been effective,with the progression of the disease,it inevitably may lead to durg resistance. In this paper,we made a review on the treatment after resistance to first generation EGFR - TKI in patients with non - small cell lung cancer.
Keywords：Non - small cell lung cancerResistanceEGFREGFR - TKI
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 722-725,740 )